Cargando…

Investigating potential mechanisms underlying FVIII inhibition in acquired hemophilia A associated with mRNA COVID‐19 vaccines

Detalles Bibliográficos
Autores principales:	Hirsiger, Julia R., Martinez, Maria, Tsakiris, Dimitrios A., Cittone, Micol G., Graf, Lukas, Oldenburg, Johannes, Pezeshkpoor, Behnaz, Recher, Mike, Mueller, Jens, Gerber, Bernhard, Berger, Christoph T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303467/ https://www.ncbi.nlm.nih.gov/pubmed/35108443 http://dx.doi.org/10.1111/jth.15665

Ejemplares similares

The statistical risk of diagnosing coincidental acquired hemophilia A following anti‐SARS‐CoV‐2 vaccination
por: Cittone, Micol G., et al.
Publicado: (2021)

Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice
por: Pezeshkpoor, Behnaz, et al.
Publicado: (2022)

An in silico and in vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII
por: Pezeshkpoor, Behnaz, et al.
Publicado: (2017)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

The Possible Non-Mutational Causes of FVIII Deficiency: Non-Coding RNAs and Acquired Hemophilia A
por: Zimta, Alina-Andreea, et al.
Publicado: (2021)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1(+) Tregs
por: Becker-Gotot, Janine, et al.
Publicado: (2022)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
por: Hemşinlioğlu, Cansu, et al.
Publicado: (2023)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
por: Hooimeijer, Louise H, et al.
Publicado: (2023)

F8 Inversions at Xq28 Causing Hemophilia A Are Associated With Specific Methylation Changes: Implication for Molecular Epigenetic Diagnosis
por: Jamil, Muhammad Ahmer, et al.
Publicado: (2019)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Case Report: mRNA vaccination-mediated STAT3 overactivation with agranulocytosis and clonal T-LGL expansion
por: Hirsiger, Julia R., et al.
Publicado: (2023)

Further Evidence That MicroRNAs Can Play a Role in Hemophilia A Disease Manifestation: F8 Gene Downregulation by miR-19b-3p and miR-186-5p
por: Jankowska, Katarzyna I., et al.
Publicado: (2020)

Synthesis of FVIII in Hemophilia-A patients with the intron-22-inversion may modulate immunogenicity
por: Pandey, Gouri Shankar, et al.
Publicado: (2013)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
por: Hart, Daniel P.
Publicado: (2020)

The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A
por: Kim, Ju Young, et al.
Publicado: (2019)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
por: Liu, Chao Lien, et al.
Publicado: (2016)

Identification of FVIII gene mutations in patients with hemophilia A using new combinatorial sequencing by hybridization
por: Chetta, M., et al.
Publicado: (2008)

Development of an FVIII Inhibitor in a Mild Hemophilia Patient with a Phe595Cys Mutation
por: Yamanouchi, Jun, et al.
Publicado: (2018)

Prevalence of FVIII Inhibitors Among Children with Hemophilia A: Experience at the Jordanian Royal Medical Services
por: Oudat, Raida, et al.
Publicado: (2020)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
por: Cai, Yuanhua, et al.
Publicado: (2020)

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
por: El-Akabawy, Nadia, et al.
Publicado: (2020)

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
por: Lytle, Allison M, et al.
Publicado: (2016)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
por: Trevisan, Brady, et al.
Publicado: (2021)

Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A
por: Elkouby, Liron, et al.
Publicado: (2021)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
por: Ai, Di, et al.
Publicado: (2022)

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication
por: Paul, Helmut, et al.
Publicado: (2022)

A graph-based machine learning framework identifies critical properties of FVIII that lead to hemophilia A
por: Ferreira, Marcos V., et al.
Publicado: (2023)

Acquired Hemophilia
por: Özsoylu, Şinasi
Publicado: (2014)

Functional Characterization of Antithrombin Mutations by Monitoring of Thrombin Inhibition Kinetics
por: Reda, Sara, et al.
Publicado: (2021)

Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors
por: Okamoto, Shuichi, et al.
Publicado: (2019)

The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.
por: Bou-Jaoudeh, Melissa, et al.
Publicado: (2023)

Limited Generalizability of a Retrospective Chart Review Comparing 3 Recombinant FVIII Products for Hemophilia A Prophylaxis
por: Preblick, Ronald, et al.
Publicado: (2020)

Utility of a high VWF:FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice
por: Raquet, Elmar, et al.
Publicado: (2015)

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
por: Kearney, Susan, et al.
Publicado: (2019)

P1662: OPTIMIZED PROPHYLAXIS BASED ON INDIVIDUALIZED TARGET TROUGH FVIII LEVEL IN PEDIATRIC PATIENTS WITH SEVERE HEMOPHILIA A
por: Huang, K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n4emo3961vns83o7m8hgp427pi